BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 9, 2019
View Archived Issues
Cytokinetics presents additional analysis data from FORTITUDE-ALS study
Read More
FDA clears IND application for a phase I study of MV-012-968 vaccine for RSV
Read More
Positive topline data reported from phase II pozelimab in patients with PNH
Read More
Sage Therapeutics reports topline data from pivotal phase III MOUNTAIN study
Read More
Epigenetic reactivation of ADGRB3 as novel therapeutic strategy in WNT-medulloblastoma
Read More
ONC-201 demonstrates clinical efficacy in patients with thalamic H3 K27M-mutant glioma
Read More
The brain - silicone's new frontier?
Read More
CC-90009 shows antileukemic activity in patients with relapsed/refractory acute myeloid leukemia
Read More
Phase I/II trial of MERT with a CXCR4 inhibitor improves local control in glioblastoma
Read More
Safety and efficacy of SST2 antagonist [177Lu]-satoreotide tetraxetan in advanced SST2+ NET
Read More
AAV2 capsid fitness landscape allows systematic optimization of natural capsids for gene therapy
Read More
ASH 2019: Gene editing can move cell therapy from biplane to Boeing era
Read More
Preliminary data presented for TN-383B in patients with relapsed or refractory multiple myeloma
Read More
HitGen presents new IL-17RA antagonists
Read More
Synlogic begins phase I study of SYNB-1891 in advanced/metastatic solid tumors and lymphoma
Read More
Lilly initiates phase I/II study of LY-3499446 in advanced solid tumors with KRAS G12C mutation
Read More
Abbisko Therapeutics identifies FGFR inhibitors
Read More
Sunshine Lake Pharma discloses mineralocorticoid receptor antagonists
Read More
Js Innomed Holdings synthesizes new ERK2 inhibitors
Read More
GlaxoSmithKline identifies new NFE2-related factor 2 activators
Read More
New phase II trial investigates OQL-011 for hand-foot skin reaction in cancer patients
Read More
Phase III BE SURE study of bimekizumab in plaque psoriasis meets coprimary endpoints
Read More
Phase III PRIMROSE 2 trial of linzagolix for heavy menstrual bleeding meets endpoints
Read More
Partial clinical hold for pediatric patients in Ipsen's FOP and MO studies of palovarotene
Read More
Phase III study of nadofaragene firadenovec in bladder cancer meets primary endpoint
Read More
